All Outputs (11)

Insight into glucocorticoid receptor signalling through interactome model analysis (2017)
Journal Article
Bakker, E., Tian, K., Mutti, L., Demonacos, C., Schwartz, J., & Krstic-Demonacos, M. (2017). Insight into glucocorticoid receptor signalling through interactome model analysis. PLoS Computational Biology, 13(11), https://doi.org/10.1371/journal.pcbi.1005825

Glucocorticoid hormones (GCs) are used to treat a variety of diseases because of their potent anti-inflammatory effect and their ability to induce apoptosis in lymphoid malignancies through the glucocorticoid receptor (GR). Despite ongoing research,... Read More about Insight into glucocorticoid receptor signalling through interactome model analysis.

Immunotherapy advances for mesothelioma treatment (2017)
Journal Article
Bakker, E., Guazzelli, A., Ashtiani, F., Demonacos, C., Krstic-Demonacos, M., & Mutti, L. (2017). Immunotherapy advances for mesothelioma treatment. Expert Review of Anticancer Therapy, 17(9), 799-814. https://doi.org/10.1080/14737140.2017.1358091

Introduction: Mesothelioma is a rare type of cancer that is strongly tied to asbestos exposure. Despite application of different modalities such as chemotherapy, radiotherapy and surgery, patient prognosis remains very poor and therapies are ineffect... Read More about Immunotherapy advances for mesothelioma treatment.

Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma (2017)
Journal Article
Guazzelli, A., Bakker, E., Tian, K., Demonacos, C., Krstic- Demonacos, M., & Mutti, L. (2017). Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma. Expert Opinion on Investigational Drugs, 26(8), 933-944. https://doi.org/10.1080/13543784.2017.1351545

Introduction: Malignant mesothelioma is a rare and lethal malignancy primarily affecting the pleura and peritoneum. Mesothelioma incidence is expected to increase worldwide and current treatments remain ineffective, leading to poor prognosis. Within... Read More about Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.

Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism (2017)
Journal Article
De Santi, C., Melaiu, O., Bonotti, A., Cascione, L., Di Leva, G., Foddis, R., …Landi, S. (2017). Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. Scientific reports, 7(2017), #3140. https://doi.org/10.1038/s41598-017-02694-0

Malignant pleural mesothelioma (MPM) is an aggressive human cancer and miRNAs can play a key-role for this disease. In order to broaden the knowledge in this field, the miRNA expression was investigated in a large series of MPM to discover new pathwa... Read More about Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.

Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia (2017)
Journal Article
Qattan, M., Bakker, E., Rajendran, R., Wei-Chen Chen, D., Saha, V., Liu, J., …Krstic- Demonacos, M. (2017). Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia. PLoS ONE, 12(6), e0178606. https://doi.org/10.1371/journal.pone.0178606

Glucocorticoids (GCs) and topoisomerase II inhibitors are used to treat acute lymphoblastic leukaemia (ALL) as they induce death in lymphoid cells through the glucocorticoid receptor (GR) and p53 respectively. Mechanisms underlying ALL cell death and... Read More about Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia.

The inhibition of FGF receptor 1 activity mediates sorafenib-induced antiproliferative effects in human mesothelioma tumor-initiating cells (2017)
Journal Article
Pattarozzi, A., Carra, E., Favoni, R., Würth, R., Marubbi, D., Filiberti, R., …Daga, A. (2017). The inhibition of FGF receptor 1 activity mediates sorafenib-induced antiproliferative effects in human mesothelioma tumor-initiating cells. Stem Cell Research and Therapy, 8(119), https://doi.org/10.1186/s13287-017-0573-7

Tumor-initiating cells (TICs), the subset of cells within tumors endowed with stem-like features, being highly resistant to conventional cytotoxic drugs, are the major cause of tumor relapse. The identification of molecules able to target TICs remain... Read More about The inhibition of FGF receptor 1 activity mediates sorafenib-induced antiproliferative effects in human mesothelioma tumor-initiating cells.

Current and prospective pharmacotherapies for the treatment of pleural mesothelioma (2017)
Journal Article
Bakker, E., Guazzelli, A., Krstic-Demonacos, M., Lisanti, M., Sotgia, F., & Mutti, L. (2017). Current and prospective pharmacotherapies for the treatment of pleural mesothelioma. Expert Opinion on Orphan Drugs, 5(6), 455-465. https://doi.org/10.1080/21678707.2017.1325358

Introduction: Mesothelioma is a rare asbestos-linked cancer with an expected incidence peak between 2015–2030. Therapies remain ineffective, thus developing and testing novel treatments is important for both oncologists and researchers. Areas co... Read More about Current and prospective pharmacotherapies for the treatment of pleural mesothelioma.

Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals (2017)
Journal Article
De Santi, C., Pucci, P., Bonotti, A., Melaiu, O., Cipollini, M., Silvestri, R., …Landi, S. (2017). Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals. Occupational and Environmental Medicine, 74(6), 457-464. https://doi.org/10.1136/oemed-2016-104024

BACKGROUND: Soluble mesothelin-related peptide (SMRP) is a promising diagnostic biomarker for malignant pleural mesothelioma (MPM), but various confounders hinder its usefulness in surveillance programmes. We previously showed that a single nucleoti... Read More about Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.

Anti-CTLA-4 therapy for malignant mesothelioma (2017)
Journal Article
Guazzelli, A., Bakker, E., Krstic-Demonacos, M., Lisanti, M., Sotgia, F., & Mutti, L. (2017). Anti-CTLA-4 therapy for malignant mesothelioma. Immunotherapy, 9(3), 273-280. https://doi.org/10.2217/imt-2016-0123

Immunotherapy is an emerging therapeutic strategy with a promising clinical outcome in some solid tumors, particularly metastatic melanoma. One approach to immunotherapy is immune checkpoint inhibitors, such as blockage of CTLA-4 and PD-1/PD-L1. This... Read More about Anti-CTLA-4 therapy for malignant mesothelioma.

Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines (2017)
Journal Article
Melaiu, O., Catalano, C., De Santi, C., Cipollini, M., Figlioli, G., Pellè, L., …Landi, S. (2017). Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines. Genes and Cancer, 8(1-2), 438-452. https://doi.org/10.18632/genesandcancer.129

Malignant pleural mesothelioma (MPM) is a cancer of the pleural cavity resistant to chemotherapy. The identification of novel therapeutic targets is needed to improve its poor prognosis. Following a review of literature and a screening of specimens w... Read More about Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines.

Switching off malignant mesothelioma : exploiting the hypoxic microenvironment (2017)
Journal Article
Nabavi, N., Bennewith, K., Churg, A., Wang, Y., Collins, C., & Mutti, L. (2017). Switching off malignant mesothelioma : exploiting the hypoxic microenvironment. Genes and Cancer, 7(11-12), 340-354. https://doi.org/10.18632/genesandcancer.124

Malignant mesotheliomas are aggressive, asbestos-related cancers with poor patient prognosis, typically arising in the mesothelial surfaces of tissues in pleural and peritoneal cavity. The relative unspecific symptoms of mesotheliomas, misdiagnoses,... Read More about Switching off malignant mesothelioma : exploiting the hypoxic microenvironment.